About dupilumab
Interleukin-4 receptor alpha antagonist
Used for
- Atopic dermatitis (eczema)
- Asthma with certain inflammatory features
- Chronic rhinosinusitis with nasal polyps
- Eosinophilic esophagitis and prurigo nodularis
Usual adult dose
Usually 300 mg every two weeks for eczema, asthma, nasal polyps, or prurigo nodularis; some conditions use a different schedule.
Usual dose in children
For eczema from 6 months: weight-based doses every 2–4 weeks. For asthma from 6 years: weight-based doses every 2–4 weeks.
Common side effects
- Injection-site reactions
- Eye inflammation or irritation
- Cold sores
- Joint pain
Important warnings
- Seek prompt assessment for severe allergic reactions.
- Asthma medicines should not be stopped suddenly when starting dupilumab.
- Report new or worsening eye symptoms.
- Worm infections may need treatment before starting.
Pregnancy
Human pregnancy information is limited; use depends on weighing potential benefits and risks.
Breastfeeding
It is unknown whether dupilumab passes into breast milk; discuss benefits and potential risks.
Interactions
- Live vaccines may be unsuitable during treatment.
- Avoid combining with other biologic medicines unless specifically directed.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.